Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) — Market Cap & Net Worth
Market Cap & Net Worth: Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) has a market capitalization of $4.62 Million ($4.62 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28694 globally and #5806 in its home market, demonstrating a -13.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liminatus Pharma, Inc. Class A Common Stock's stock price $0.10 by its total outstanding shares 44877633 (44.88 Million). Review LIMN total liabilities to assess the company's total debt and financial obligations.
Liminatus Pharma, Inc. Class A Common Stock Market Cap History: 2025 to 2026
Liminatus Pharma, Inc. Class A Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $27.38 Million to $4.62 Million (0.00% CAGR).
Liminatus Pharma, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIMN by Market Capitalization
Companies near Liminatus Pharma, Inc. Class A Common Stock in the global market cap rankings as of August 3, 2026.
Key companies related to Liminatus Pharma, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Liminatus Pharma, Inc. Class A Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Liminatus Pharma, Inc. Class A Common Stock's market cap moved from $27.38 Million to $ 4.62 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.62 Million | -83.11% |
| 2025 | $27.38 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Liminatus Pharma, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.62 Million USD |
| MoneyControl | $4.62 Million USD |
| MarketWatch | $4.62 Million USD |
| marketcap.company | $4.62 Million USD |
| Reuters | $4.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.